Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA User Fees Could Fund Responses To DTC Ads, AARP Says

Executive Summary

The federal government should sponsor public information campaigns to supplement the information supplied by direct-to-consumer advertising of pharmaceuticals, an AARP Public Policy Institute "issue paper" on DTC ads states.

You may also be interested in...



FDA To Discuss "PDUFA III" Agenda At September Meeting

FDA is soliciting public input into its goals for reauthorization of the Prescription Drug User Fee Act.

FDA To Discuss "PDUFA III" Agenda At September Meeting

FDA is soliciting public input into its goals for reauthorization of the Prescription Drug User Fee Act.

Rx Marketing Needs "Independent Voice" In Washington - AAAA's Kamp

Pharmaceutical marketing groups should consider establishing an "independent voice" to address political issues from the point of view of advertisers, AAAA Senior VP John Kamp told the Healthcare Marketing & Communications Council meeting in Basking Ridge, N.J. May 11.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel